Differences in patient and tumour characteristics (discussed in the following section) distinguish BRAFm+ melanoma as a disease that is distinct from wild-type BRAF.
Patients with BRAF mutation have been shown in multiple studies to be diagnosed with metastatic disease at an earlier age, which has been identified as a negative prognostic factor in melanoma.1-5
In contrast to patients with wild-type BRAF, BRAF mutation is more frequently observed in patients who have had indirect, intermittent exposure to the sun.6
The location at which primary tumours present has been associated with BRAF mutation status. Significantly more patients with BRAF mutation
present with localised disease on the truncal region (see figure below).1-3,6
Additionally, BRAF mutation tumours are more than two times as likely to exhibit superficial spreading compared with wild-type BRAF disease (see figure below).1,2
Recognising these characteristics associated with BRAFm+ melanoma can help to identify patients and distinguish their disease from wild-type BRAF.